GlassScriptPhysician profile
William B Weiss
NPI 1568650919
$1,143.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.77 · 2020: $45.76 · 2021: $523 · 2022: $547.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $380.97 | 2020-2022 | |
| Glaxosmithkline, LLC. | $353.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.40 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $72.46 | 2021-2022 | |
| Genzyme Corporation | $43.73 | 2020-2021 | |
| Electromed, INC. | $38.37 | 2021-2022 | |
| Insmed, INC. | $33.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.37 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.89 | 2022 | |
| Philips North America LLC | $14.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2019 | |
| Gilead Sciences, INC. | $13.66 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.